Is adipose tissue a reservoir for viral spread, immune activation and cytokine amplification in COVID-19? by Ryan, Paul MacDaragh & Caplice, Noel M.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Is adipose tissue a reservoir for viral spread, immune activation and
cytokine amplification in COVID-19?
Author(s) Ryan, Paul MacDaragh; Caplice, Noel M.
Publication date 2020-04-21
Original citation Ryan, P. M. and Caplice, N. M. (2020) 'Is adipose tissue a reservoir for
viral spread, immune activation and cytokine amplification in COVID-
19?', Obesity. doi: 10.1002/oby.22843




Access to the full text of the published version may require a
subscription.
Rights © 2020, the Obesity Society. Published by John Wiley & Sons, Inc.
This is the peer reviewed version of the following article: Ryan, P.
M. and Caplice, N. M. (2020) 'Is adipose tissue a reservoir for viral
spread, immune activation and cytokine amplification in COVID-
19?', Obesity, doi: 10.1002/oby.22843, which has been published in
final form at https://doi.org/10.1002/oby.22843. This article may be
used for non-commercial purposes in accordance with Wiley Terms
and Conditions for Use of Self-Archived Versions.
Embargo information Access to this article is restricted until 12 months after publication by
request of the publisher.





This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1002/oby.22843
 This article is protected by copyright. All rights reserved
DR. PAUL MACDARAGH RYAN (Orcid ID : 0000-0001-7251-6725)
Article type      : Review
Is Adipose Tissue a Reservoir for Viral Spread, Immune 
Activation and Cytokine Amplification 
in COVID-19
Paul MacDaragh Ryan, Noel M Caplice
Centre for Research in Vascular Biology,














This article is protected by copyright. All rights reserved
Address for correspondence:
Prof. Noel M Caplice M.D., Ph.D.
Centre for Research in Vascular Biology,
APC Microbiome Ireland
Cork University Hospital, 
University College Cork, 
Cork, Ireland
Tel: int + 353 871201487
Email: n.caplice@ucc.ie
Funding: No extramural funding was sought for this manuscript.










This article is protected by copyright. All rights reserved
ABSTRACT
Coronavirus disease 2019 (COVID-19), the worst pandemic in more than a century, has claimed 
>125,000 lives worldwide to date. Emerging predictors for poor outcome include advanced age, 
male gender, pre-existing cardiovascular disease and risk factors including hypertension, 
diabetes and more recently obesity. Herein, we posit new obesity-driven predictors of poor 
COVID-19 outcome, over and above the more obvious extant risks associated with obesity 
including cardiometabolic disease and hypoventilation syndrome in intensive care patients. We 
outline a theoretical mechanistic framework whereby adipose tissue in subjects with obesity may 
act as a reservoir for more extensive viral spread with increased shedding, immune activation 
and cytokine amplification. We propose studies to test this reservoir concept with a focus on 
specific cytokine pathways that might be amplified in subjects with obesity and COVID-19. 
Finally, we underscore emerging therapeutic strategies that might benefit subsets of patients in 
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Coronavirus disease 2019 (COVID-19) has now infected over 2 million people worldwide, with a 
death toll of more than 125,000 people. Emerging risk factors for poor outcome in this disease 
include age, male gender, cardiovascular co-morbidities including hypertension, prior 
cardiovascular disease, diabetes and more recently obesity (1). The Center for Disease Control 
and Prevention (CDC, Atlanta, USA) has now reported a 3-fold increase in death in New Orleans 
compared to New York and speculation has grown as to whether these worrying mortality 
statistics might in part be attributable to higher levels of morbid obesity (2). In this perspective 
paper we develop a theoretical framework that describes why subjects with obesity may be at 
increased risk of poor outcomes compared to non-obese counterparts (3). We propose a 
mechanism for adverse consequences of virus seeding to adipose tissue (AT) with potential for 
prolonged viral shedding and extended cytokine activation in a voluminous and richly 
vascularized organ that is already perturbed in a metabolic and inflammatory sense in human 
subjects with obesity (4). We present a rationale for testing this concept in COVID-19 patients 
through prospective studies of subjects with and without obesity with accessible adipose tissue 
and plasma to determine whether or not an inflammatory and cytokine signature presages a 
systemic cytokine storm and clinical decline.
Evidence for association of obesity with worse COVID-19 outcome
Obesity was not specifically reported in the initial cohort studies of COVID-19 from Wuhan, China 
(5) but regional epidemiological data from the USA suggests that at least 25% of patients who die 
of this disease have obesity, which is similar to reported rates of cardiovascular disease in the 
same high risk group (21%) (6). More recently, a small retrospective study of 85 subjects with 
COVID-19 identified obesity as a risk factor for admission to ICU with patients requiring increased 
medical attention (3). Moreover, in the influenza A subtype H1N1 pandemic, obesity was also 
strongly associated with a worse disease outcome and death (7). Together these data raise the 
question of whether there is a mechanistic link between obesity and disease survival, and 
whether obesity over and above its endocrine or cardiometabolic associations might 
independently contribute to COVID-19 risk.
Likely mechanisms involved in poor outcomes in subjects with obesity
It is clear that obesity could contribute to both diabetic and cardiovascular risk of COVID-19  and 
these elements of risk, in addition to more recently thrombosis, have been well described in the 
scientific literature (8, 9, 10, 11, 12). Moreover, obesity is an independent risk for 
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patients with acute respiratory distress syndrome (ARDS) (14). Here, we propose additional 
unheralded pathophysiologic aspects of increased AT burden in morbid obesity that may amplify 
the pro-inflammatory response to extensive viral infection. AT should be viewed as a highly active 
organ interfacing immune, endocrine and metabolic homeostasis throughout the body (15). In 
subjects with obesity there is marked dysregulation of myeloid and lymphoid responses within AT 
with associated dysregulation of cytokine profiles (15). Intrinsically bound to this are endocrine 
and metabolic derangements including insulin resistance, and adipokine dysregulation with 
dysfunctional lipid and fatty acid metabolism (16). In highly vascularized adipose tissue, 
endothelial and smooth muscle cells as well as resident macrophages exhibit additional 
perturbations in response to an activated renin angiotensin system (RAS) at a local level with 
attendant depletion and dysfunction of the counter-regulatory angiotensin converting enzyme 2 
(ACE2) Mas receptor system (17, 18). This makes AT, particularly in visceral distributions, pro-
immunogenic, metabolically active and highly integrated into the cardiovascular system, with the 
capability to drive acute disease through augmented inflammation at an organ level in the heart, 
vasculature, pancreas, liver and kidneys (19). This “pre-activation state” of AT in obesity makes 
this organ a potential target for further immune amplification by external pathogens such as 
viruses.
Viral spread to AT and potential for activation of resident inflammation and cytokine 
pathways 
Currently there is no evidence for direct SARS-CoV-2 infection of AT, although ACE2 receptor 
expression represents a basis for viral tropism in several cells within this tissue (20) including 
adipocytes, smooth muscle cells and endothelial cells (21). Moreover, many AT-resident cells are 
proven targets for multiple viruses including adipocytes (H1N1, Type A influenza and adenovirus 
36 (7, 22, 23)), adipo-stromal cells (Adenovirus 36 (24), CMV (25)), endothelial cells (SARS-CoV 
(26)), macrophages (influenza A, SARS-CoV, adenovirus36, HIV (26, 27)) and lymphocytes 
(SARS-CoV, HIV  (25, 26)). Although SARS-CoV-2 was detected only at low levels in blood in a 
small human study (28), we cannot exclude hematogenous spread to AT given very high virus 
affinity for its target cell receptor. Alternative routes of SARS-CoV-2 spread to AT include local 
egress of virus, from organs known to be infected, to adjacent visceral fat deposits such as 
intrathoracic fat (lungs), epicardial fat (heart), peri-renal fat (kidneys) and mesenteric fat 
(intestines). Finally, shared viral tropism for lung epithelium and adipose tissue has already been 
shown for H5N1 virus infection (29) and AT significantly prolongs the duration of viral shedding in 
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within AT of COVID-19 subjects with obesity there exists the potential for prolonged viral 
shedding in this organ with extended activation of local “pre-activated” immune systems and 
resident cytokine signalling pathways. 
Resident myeloid and lymphoid cells are plentiful in AT and obesity is associated with 
macrophage (30) and lymphocyte dysfunction (31). Expansion of distinct memory T lymphocytes 
within AT can also activate aberrant immune responses with wider tissue damage on viral 
challenge (31). A recent report from Wuhan suggests that SARS-CoV-2 induces a dysregulated 
immune response in severely ill COVID-19 subjects (32), characterised by reduced numbers of 
circulating memory T lymphocytes, as well as reduced helper / suppressor T cell and T Reg 
subtypes. It is tempting to speculate whether already dysfunctional immune responses in subjects 
with obesity may accentuate this SARS-CoV-2 effect on T cell function. 
Specific inflammatory cytokine programmes such TNF, IL1 and IL6 are known to be pre-
activated in AT in the context of obesity (33) and, thus, viral infection may similarly amplify the 
already primed organ cytokine response in AT. The cytokine storm identified in multiple 
respiratory viral infections including COVID-19 exhibits diverse interferon, interleukin, chemokine, 
tumor necrosis factor and colony stimulating factor responses which are beyond the scope of this 
perspective, but comprehensively reviewed elsewhere (34). The intensity of inflammatory lung 
responses reflect the imbalance between proinflammatory cytokines (such as TNF and Il1) and 
their soluble cognate receptors that inhibit cytokine effects in aqueous phase (35). IL10 produced 
by macrophages and T lymphocytes (Th2 and T regs) acts as a negative regulator of 
inflammation; whereas IL6 and its soluble receptor enhance activity of IL6 on target cells 
providing a mechanism for enhancement of TNF and IL-1 activity when these soluble cognate 
receptor are particularly high (35). Thus, a balance between pro- and anti-inflammatory 
mechanisms is critical in maintaining lung tissue homeostasis. It is conceivable that if one or 
more of these regulatory elements were absent or dysfunctional then this may contribute to a 
cytokine storm in the lung or in other tissues such as AT where aberrant cytokine activation 
exists. Temporal studies of cytokine dynamics in human “cytokine storm” models show IL6 
sustains activation of multiple cytokine pathways for many days post initial immune insult (36). 
Interestingly, in early COVID-19 studies IL6 was a strong independent predictor of mortality (37). 
Human AT is a major source of IL6 and its receptor IL6R (38) and, thus, AT may provide a 
reservoir for IL6 activation and cascade signalling in viral infection (Figure). Viral spread from 
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contributing to the delayed cytokine storm and consequences for tissue injury in patients with 
COVID-19.
Testing AT inflammatory cytokine reservoir concept in COVID-19
Initial studies should aim to detect SARS-CoV-2 in AT upon autopsy of subjects who have died of 
COVID-19. Focus should be on analysis of specific cells that have evidence of infection by 
immunocytopathic and in situ viral detection techniques. Parallel studies should identify whether 
specific cell types in AT can support SARS-CoV-2 infection and replication ex vivo. With respect 
to cytokine storm, an integrated systems biology approach would enable multiple pathways to be 
assessed simultaneously. In this regard, cytokine and chemokine genomic data analysis in blood 
and AT would be an important first step. Moreover a weighted gene correlation network analysis 
of SARS-CoV-2 mediated transcriptional response in infected cells could also be used as a 
model for human AT analysis downstream (39). Interesting aspects of transcriptional network 
analysis could then be tested in appropriate animal models to determine pivotal components of 
the cytokine storm including key cytokine and chemokine genes that are conserved across 
species (40). These insights may allow rational diagnostics and therapeutic strategies to be 
developed. In line with this, IL6 inhibition has already been proposed as a treatment in COVID-19 
and the results of trials of Tocilizumab are awaited (41). It would be interesting to examine 
whether subjects with obesity, who are expected to have higher circulating IL6 levels compared 
to lean counterparts, respond more favourably to IL6 inhibition strategies in COVID-19 in a post 
hoc analysis of this RCT. Similarly, tissue and systemic analysis of cytokine dynamics may 
identify likely responders and non-responders to such therapy.
In summary we present a rationale for studying the relationship between obesity and COVID-19 
disease severity. We provide a theoretical framework whereby viral systemic spread, entry and 
prolonged viral shedding in already “inflamed” AT may augment immune responses with 
consequences for cytokine cascade amplification. We highlight AT as an abundant source for 
local and systemic enrichment of cytokines, some already independently associated with 
increased COVID-19 mortality. Finally we suggest a series of research studies to identify whether 
a mechanistic link exists between AT, SARS-CoV-2 infection, organ seeding of infection, immune 
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FIGURE LEGEND
Figure. Adipose Tissue as a Reservoir for SARS-CoV-2 Spread, Viral Shedding, Immune 
Activation and Cytokine Amplification. Schematic demonstrating the proposed centrality of 
adipose tissue in the dissemination of SARS-CoV-2 and the ensuing systemic immune activation. 
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